endothelin-2

Endothelin-2 (49-69), human (TFA) is a 21-amino acid vasoactive peptide that binds to ET-RA and ET-RB.

Endothelin-2 (49-69), human (Human endothelin-2) 是一种由 21 个氨基酸组成的血管活性肽。它可与 G 蛋白连接的跨膜受体，ET-RA 和ET-RB 结合。

N-(6-chloro-5-(2-Methoxyphenoxy)-2-(pyridin-4-yl)pyriMidin-4-yl)-5-Met 抑制内皮素与CHO 细胞膜上人ETA 受体和人ETB 受体的的结合,IC50分别为268nM 和 1810nM。

Avosentan（Ro 67-0565; SPP-301） 是有效的内皮素受体（ETA）拮抗剂,对内皮素-1诱导的收缩有很强的抑制作用,可能对慢性肾脏疾病具有保护作用。[2]

A-192621 is a potent, nonpeptide, orally active and selective endothelin B (ETB) receptor antagonist with an IC50 of 4.5 nM and a Ki of 8.8 nM. A-192621 promotes apoptosis in PASMCs and it also causes elevation of arterial blood pressure and an elevation

Nebentan (YM598) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan . Nebentan inhibits [125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively[1]. YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo[2]. Nebentan inhibits the specific binding of [125I] endothelin-1 to endothelin ETA and ETB receptors in a concentration dependent manner,Ki values are 0.697 nM and 1.53 nM for human and rat endothelin ETA receptors, respectively. In contrast, YM598 exhibits low affinities for human and rat endothelin ETB receptors, with Ki values of 569 nM and 155 nM,respectively[1].In measurement of intracellular Ca2+ concentration, Nebentan concentration-dependently inhibits the increase in [Ca2+]i induced by 10 nM endothelin-1 in both CHO cells and A10 cells, the IC50 values are 26.2 nM for CHO cells and 26.7 nM for A10 cells, respectively[1]. Nebentan (oral administration; 0.1-1 mg kg; 4 weeks) significantly inhibits the progression of pulmonary hypertension and the development of right ventricular hypertrophy[2].Nebentan (oral administration; 1 mg kg; 30 weeks) significantly ameliorates the poor survival rate of CHF rats, it markedly reduces the hypertrophy of both ventricles as well as pulmonary congestion[2]. [1]. Hironori Yuyama, et al. Pharmacological Characterization of YM598, an Orally Active and Highly Potent Selective Endothelin ET(A) Receptor Antagonist. Eur J Pharmacol. 2003 Sep 30;478(1):61-71. [2]. Akira Fujimori, et al. YM598, an Orally Active ET(A) Receptor Antagonist, Ameliorates the Progression of Cardiopulmonary Changes and Both-Side Heart Failure in Rats With Cor Pulmonale and Myocardial Infarction. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S354-7.

BE-24566B is a polyketide fungal metabolite originally isolated fromS. violaceusniger.1It is active againstB. subtilis,B. cereus,S. aureus,M. luteus,E. faecalis, andS. thermophilus(MICs = 1.56, 1.56, 1.56, 1.56, 3.13, and 3.13 μg/ml, respectively). BE-24566B is an endothelin (ET) receptor antagonist (IC50s = 11 and 3.9 μM for ETAand ETBreceptors, respectively).2 1.Kojiri, K., Nakajima, S., Fuse, A., et al.BE-24566B, a new antibiotic produced by Streptomyces violaceusnigerJ. Antibiot. (Tokyo)48(12)1506-1508(1995) 2.Lam, Y.K.T., Hensens, O., Helms, G., et al.L-755,805, a new polyketide endothelin binding inhibitor from an actinomyceteTetrahedron Lett.36(12)2013-2016(1995)

Sulfisoxazole diethanolamine, also known as Sulfafurazole diethanolamine, is a sulfonamide antibacterial compound with an oxazole substituent. It acts as an endothelin receptor antagonist, specifically targeting endothelin receptor A with an IC50 value of 0.60 μM and endothelin receptor B with an IC50 value of 22 μM. Additionally, Sulfisoxazole diethanolamine has been found to inhibit the release of breast cancer exosomes by specifically targeting endothelin receptor A [1] [2].

Zibotentan (ZD4054) 是一种选择性的，具有口服活性的内皮素 A (ETA) 受体拮抗剂，Ki 为 13 nM。它具有抗癌作用，可研究去势抵抗性前列腺癌。

BQ-123 是高效的内皮素 A(ETA)受体选择性拮抗剂，其IC50=7.3 nM，Ki=25 nM。它能够降低高血压大鼠血压，抑制内皮素-1 介导的人肺动脉平滑肌细胞增殖。

BQ-123 TFA 是一种高效、选择性内皮素 A(ETA)受体拮抗剂，IC50值为 7.3 nM，Ki 值为 25 nM。BQ-123 TFA 抑制内皮素-1 介导的人肺动脉平滑肌细胞增殖，降低高血压大鼠血压。

SAR407899 是一种选择性的 ATP 竞争性ROCK 抑制剂，对ROCK-2的IC50值为 135 nM，对人和大鼠ROCK-2的Ki 值分别为 36 和 41 nM。它是 Rho 激酶抑制剂，有效抑制 endothelin-1 诱导的肾阻力动脉收缩。

[Ala2] Endothelin-3, human 为ET-3的线性类似物，其结构中的Cys残基被Ala所替代。ET-3是由人体横纹肌肉瘤细胞系产生，且仅在此细胞系中表达的一种具有血管活性的肽。在非肌肉来源的肉瘤细胞系中不表达。该肽能够作为旁分泌因子，促进内皮细胞迁移。

BQ-3020 ammonium 是一种内皮素受体（endothelin receptor）(ETB receptor) 激动剂。它在阻断[125I]ET-1与猪小脑ETB受体的结合实验中显示出IC50值为0.2 nM。此外，BQ-3020 ammonium能够引致兔肺动脉血管收缩以及猪膀胱颈的松弛，因此可作为心血管疾病研究的工具。

Aprocitentan (ACT-132577) 是一种 Macitentan 的主要活性代谢物。它是 ETA/ETB 的双重拮抗剂，其 pA2值分别为 6.7 和 5.5，IC50分别为 3.4 nM 和 987 nM。

Endothelin-1 is one of the there isoforms of endothelin (identified as ET-1, -2, -3) with varying regions of expression and binding to at least four known endothelin receptors, ETA, ETB1, ETB2 and ETC.

JKC 301, a selective Endothelin A receptor antagonist, attenuates the pressor effects of nicotine in rats and can be used to study cardiovascular disease caused by smoking [1] [2].

Vasoactive intestinal contractor, a novel member of the endothelin family, stimulates a rapid increase in intracellular Ca2+ concentration in fura-2-overexpressed Swiss 3T3 cells [1.